-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on ImmunityBio, Raises Price Target to $7

Benzinga·01/20/2026 13:20:11
Listen to the news
Piper Sandler analyst Joseph Catanzaro maintains ImmunityBio (NASDAQ:IBRX) with a Overweight and raises the price target from $5 to $7.